Tiziana Life Sciences (NASDAQ:TLSA) Trading Down 0.9% – Time to Sell?

Shares of Tiziana Life Sciences Ltd (NASDAQ:TLSA) were down 0.9% during trading on Thursday . The stock traded as low as $1.05 and last traded at $1.08. Approximately 272,314 shares changed hands during mid-day trading, a decline of 77% from the average daily volume of 1,175,750 shares. The stock had previously closed at $1.09.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Zacks Research raised shares of Tiziana Life Sciences to a “hold” rating in a research report on Tuesday, July 14th. Weiss Ratings reissued a “sell (e+)” rating on shares of Tiziana Life Sciences in a research report on Wednesday. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Tiziana Life Sciences presently has an average rating of “Reduce”.

Tiziana Life Sciences Price Performance

The business has a 50 day simple moving average of $1.10 and a 200-day simple moving average of $1.25.

Insiders Place Their Bets

In related news, CEO Ivor Elrifi acquired 667,000 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The stock was acquired at an average price of $1.00 per share, for a total transaction of $667,000.00. Following the completion of the acquisition, the chief executive officer owned 4,472,261 shares of the company’s stock, valued at approximately $4,472,261. This represents a 17.53% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders have bought a total of 988,423 shares of company stock worth $985,909 in the last three months. 39.82% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Bison Wealth LLC purchased a new stake in shares of Tiziana Life Sciences during the 4th quarter worth approximately $30,000. Zhang Financial LLC lifted its stake in Tiziana Life Sciences by 12.0% in the first quarter. Zhang Financial LLC now owns 111,900 shares of the company’s stock valued at $131,000 after purchasing an additional 12,000 shares during the last quarter. OMERS ADMINISTRATION Corp purchased a new position in Tiziana Life Sciences in the fourth quarter valued at approximately $59,000. Marshall Wace LLP grew its holdings in Tiziana Life Sciences by 5.2% during the fourth quarter. Marshall Wace LLP now owns 282,017 shares of the company’s stock valued at $420,000 after purchasing an additional 14,005 shares during the period. Finally, Goldman Sachs Group Inc. grew its holdings in Tiziana Life Sciences by 413.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 110,290 shares of the company’s stock valued at $164,000 after purchasing an additional 88,830 shares during the period.

About Tiziana Life Sciences

Tiziana Life Sciences plc (NASDAQ: TLSA) is a clinical-stage biotechnology company focused on the development of novel therapeutics in the fields of oncology, immunology and infectious diseases. Headquartered in London, with research and development operations in Cambridge, Massachusetts, the company advances both small-molecule inhibitors and monoclonal antibody candidates designed to modulate immune pathways and target tumor growth.

The company’s lead small‐molecule program, milciclib, is an oral cyclin‐dependent kinase inhibitor currently in Phase II clinical trials for hepatocellular carcinoma and certain neuroendocrine tumors.